Endocrine-metabolic effects of l-carnitine in patients on regular dialysis treatment.
Twenty-three patients on regular dialysis treatment (RDT) were given 1-carnitine orally or in dialysate for six months. All patients remained in a stable biochemical state; hyperlipidaemia was reduced with an increase in HDL-cholesterol. Hormonal pattern was unmodified. Serum and muscle carnitine and acetylcarnitine constantly increased. L-carnitine in RDT, by restoring tissue reserves, improves metabolic alterations without any side-effects.
D000108:Acetylcarnitine / Q000378:metabolism; D000293:Adolescent; D000328:Adult; D000368:Aged; D002331:Carnitine / Q000378:metabolism / Q000627:therapeutic use*; D002784:Cholesterol / Q000378:metabolism; D008076:Cholesterol, HDL; D005260:Female; D006728:Hormones / Q000378:metabolism; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000378:metabolism / Q000628:therapy*; D008075:Lipoproteins, HDL / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000378:metabolism*; D006435:Renal Dialysis
D008076:Cholesterol, HDL; D006728:Hormones; D008075:Lipoproteins, HDL; D000108:Acetylcarnitine; D002784:Cholesterol; D002331:Carnitine